PolyProx Therapeutics was incorporated in November 2018 and recently completed its Seed Financing, raising £3.4m from Cambridge Innovation Capital plc, RT Capital and Cambridge Enterprise.
Cambridge Innovation Capital (CIC) is a venture capital investor in IP-rich technology and life science businesses in the Cambridge ecosystem. CIC is committed to building leading businesses from brilliant technologies. It combines a unique relationship with the University of Cambridge with deep financial and industry links to support these businesses as they seek to fulfil their potential and to change the world of tomorrow.
Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge and is responsible for the commercialisation of University intellectual property. It provides access to early stage capital through the Cambridge Enterprise Seed Funds, University of Cambridge Enterprise Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and related programmes. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations.
RT Capital is a fund managed by RT Partners, a boutique investment firm focused on UK IP-rich technology, with a particular emphasis on bio-tech and genomics. It invests in seed, Series A/B, and growth stage UK technology companies.